Looking for additional ICI-specific transcriptomic signatures, a similar analysis of CD4+T-cells in the same selected group of extreme individuals with advanced/metastatic melanoma (n=24) was performed to recognize candidates with greater likelihood for durable response or early relapse/progression upon immunotherapy. The gene discussed is CD4; the disease is metastatic melanoma.